Literature DB >> 7704001

Drugs recently associated with lupus syndromes.

M J Fritzler1.   

Abstract

A number of drugs have recently been implicated in a syndrome that resembles systemic lupus erythematosus. One of the difficulties in many of these patients is that the signs, symptoms and serological abnormalities reported in these patients may be a natural consequence of the primary diseases rather than the incriminated drug. A second problem with the studies is a lack of uniform reporting of the techniques used to detect autoantibodies. For example, a patient that has a highly positive ANA with a homogeneous pattern of staining or a positive LE cell test usually has antibodies directed against chromatin components (DNA, histones, high mobility group (HMG) proteins). The discrepancies in clinical criteria and the serological techniques in many of these reports, emphasize the importance of using guidelines for the diagnosis of drug-induced or drug-related lupus. In the future, it appears that the increased use of biological response modifiers such as interferon-alpha and other cytokines may prompt more reports of lupus syndromes associated with their use.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7704001     DOI: 10.1177/096120339400300605

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  11 in total

Review 1.  Drug-induced rheumatic disorders: incidence, prevention and management.

Authors:  P Vergne; P Bertin; C Bonnet; C Scotto; R Trèves
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

2.  Betaxolol and drug-induced lupus complicated by pericarditis and large pericardial effusion.

Authors:  J T Hardee; C A Roldan; T W Du Clos
Journal:  West J Med       Date:  1997-08

Review 3.  Clinical relevance of autoantibodies in systemic rheumatic diseases.

Authors:  M J Fritzler
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

4.  Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells.

Authors:  H Vallin; S Blomberg; G V Alm; B Cederblad; L Rönnblom
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

Review 5.  The Cutaneous Spectrum of Lupus Erythematosus.

Authors:  Simone Ribero; Savino Sciascia; Luca Borradori; Dan Lipsker
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

6.  Smoking history, alcohol consumption, and systemic lupus erythematosus: a case-control study.

Authors:  C J Hardy; B P Palmer; K R Muir; A J Sutton; R J Powell
Journal:  Ann Rheum Dis       Date:  1998-08       Impact factor: 19.103

7.  Carbimazole-induced lupus.

Authors:  Ihteshamul Haq; Michael D Sosin; Simon Wharton; Anindya Gupta
Journal:  BMJ Case Rep       Date:  2013-02-06

8.  Pegylated interferon alpha-2B induced lupus in a patient with chronic hepatitis B virus infection: case report.

Authors:  Sema Yilmaz; Kadriye Akar Cimen
Journal:  Clin Rheumatol       Date:  2009-08-04       Impact factor: 3.650

9.  Assessment of autoimmune responses associated with asbestos exposure in Libby, Montana, USA.

Authors:  Jean C Pfau; Jami J Sentissi; Greg Weller; Elizabeth A Putnam
Journal:  Environ Health Perspect       Date:  2005-01       Impact factor: 9.031

10.  MMP-9/Gelatinase B Degrades Immune Complexes in Systemic Lupus Erythematosus.

Authors:  Estefania Ugarte-Berzal; Lise Boon; Erik Martens; Vasily Rybakin; Daniel Blockmans; Jennifer Vandooren; Paul Proost; Ghislain Opdenakker
Journal:  Front Immunol       Date:  2019-03-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.